Literature DB >> 29249394

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

Dmitriy Zamarin1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29249394      PMCID： PMC5763147          DOI： 10.1016/j.ymthe.2017.12.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

Review 1.  The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds.

Authors:  Debbie C Crans; Jason J Smee; Ernestas Gaidamauskas; Luqin Yang
Journal:  Chem Rev       Date:  2004-02       Impact factor: 60.622

Review 2.  Protein tyrosine phosphatases and the immune response.

Authors:  Tomas Mustelin; Torkel Vang; Nunzio Bottini
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

Review 3.  Vanadium in diabetes: 100 years from Phase 0 to Phase I.

Authors:  Katherine H Thompson; Chris Orvig
Journal:  J Inorg Biochem       Date:  2006-09-07       Impact factor: 4.155

4.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

5.  Maraba virus as a potent oncolytic vaccine vector.

Authors:  Jonathan G Pol; Liang Zhang; Byram W Bridle; Kyle B Stephenson; Julien Rességuier; Stephen Hanson; Lan Chen; Natasha Kazdhan; Jonathan L Bramson; David F Stojdl; Yonghong Wan; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10-25       Impact factor: 11.454

6.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Authors:  Antoni Ribas; Reinhard Dummer; Igor Puzanov; Ari VanderWalde; Robert H I Andtbacka; Olivier Michielin; Anthony J Olszanski; Josep Malvehy; Jonathan Cebon; Eugenio Fernandez; John M Kirkwood; Thomas F Gajewski; Lisa Chen; Kevin S Gorski; Abraham A Anderson; Scott J Diede; Michael E Lassman; Jennifer Gansert; F Stephen Hodi; Georgina V Long
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

7.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

Authors:  Jason Chesney; Igor Puzanov; Frances Collichio; Parminder Singh; Mohammed M Milhem; John Glaspy; Omid Hamid; Merrick Ross; Philip Friedlander; Claus Garbe; Theodore F Logan; Axel Hauschild; Celeste Lebbé; Lisa Chen; Jenny J Kim; Jennifer Gansert; Robert H I Andtbacka; Howard L Kaufman
Journal:  J Clin Oncol       Date:  2017-10-05       Impact factor: 44.544

8.  Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells.

Authors:  Peihong Dai; Weiyi Wang; Ning Yang; Cristian Serna-Tamayo; Jacob M Ricca; Dmitriy Zamarin; Stewart Shuman; Taha Merghoub; Jedd D Wolchok; Liang Deng
Journal:  Sci Immunol       Date:  2017-05-19

9.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors.

Authors:  Mark S Diamond; Michelle Kinder; Hirokazu Matsushita; Mona Mashayekhi; Gavin P Dunn; Jessica M Archambault; Hsiaoju Lee; Cora D Arthur; J Michael White; Ulrich Kalinke; Kenneth M Murphy; Robert D Schreiber
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

10.  Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

Authors:  F Galivo; R M Diaz; P Wongthida; J Thompson; T Kottke; G Barber; A Melcher; R Vile
Journal:  Gene Ther       Date:  2009-12-17       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.